Background/Aim: We aimed to demonstrate the use of next-generation sequencing (NGS) to confirm the presence of tumor protein 53 (TP53) mutations in tuboovarian and peritoneal high-grade serous carcinoma (HGSC) with a wild-type p53 immunostaining pattern and investigate whether the TP53 mutational status is altered by chemotherapy. Materials and Methods: A commercial NGS panel comprising 171 genes was used to analyze the genetic profiles of 15 HGSC samples. Paired specimens obtained before and after chemotherapy were available for four patients. Results: All examined samples exhibited TP53 mutations. For all the patients who underwent neoadjuvant or postoperative adjuvant chemotherapy, TP53 mutations identified in samples obtained after chemotherapy were the same as those detected in pre-chemotherapeutic samples. Conclusion: HGSCs exhibit TP53 mutations even though a subset of HGSCs displayed a wild-type p53 immunostaining pattern. Chemotherapy does not affect the TP53 mutational status in HGSC.
Bibliographical noteFunding Information:
This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2018R1C1B5043725) and the Basic Science Research Program through the NRF funded by the Ministry of Education (2016R1D1A1B03935584).
© 2019 International Institute of Anticancer Research. All rights reserved.
All Science Journal Classification (ASJC) codes
- Biochemistry, Genetics and Molecular Biology(all)